The Lived Experience of People With Von Willebrand Disease — VWD360  

Von Willebrand Diseases Clinical Trial

Official title: The Lived Experience of People With Von Willebrand Disease

Status Recruiting

Clinical Trial Summary

von Willebrand disease (vWD) is reported to be the most common bleeding disorder, with prevalence estimated at 1% of the general population. Despite this, little is known about its natural history, or of the impact it has on affected individuals and their families. The Haemnet vWD360 programme is a mixed-methods, natural history study designed to gain a greater understanding of vWD and its impact on individuals and their families. It comprises both qualitative and quantitative approaches and is designed to include the perspectives of individuals with a diagnosis of any subtype of vWD. The vWD360 study includes three components: - Quantitative cross-sectional survey - Qualitative one-to-one interviews with affected individuals - 30-day bleed diary.

Clinical Trial Description

von Willebrand Disease (vWD) is an inherited blood clotting (coagulation) disorder characterized by a reduction (quantitative) or poor function (qualitative) defect of factor VIII (FVIII) and/or von Willebrand factor (vWF). There are numerous subtypes categorised as: - Type 1: a quantitative defect characterised by decreased levels of vWF in the circulation. Many affected individuals have a mild bleeding phenotype but may have heavy menstrual bleeding (HMB) and bleed following trauma/surgery. - Type 2: a qualitative defect that is further divided into four subtypes - Type 2A - vWF is unable to bind to form the large vWF multimers required for coagulation - Type 2B - vWF has enhanced binding to platelet glycoprotein Ib (GPIb), causing rapid clearance of platelets and an associated thrombocytopenia - Type 2M - vWF has a decreased ability to bind to GPIb - Type 2N - there is a deficiency of vWF binding to FVIII - Type 3: the most severe vWD subtype, characterised by complete absence of vWF production and an inability to bind with FVIII, resulting in a severely reduced FVIII level. Acquired vWD can develop as an autoimmune disorder, as a result of cancer, some cardiac conditions or following of certain drugs. It will not be considered as part of this study.vWD is characterized by prolonged or spontaneous bleeding from birth. Affected individuals tend to bruise easily, may have frequent nosebleeds (epistaxis), may bleed from the gums, bleeding within tissues (haematoma), in the gastrointestinal tract (more common later in life) and joint bleeds (in Type 3). vWD causes prolonged bleeding following injury, trauma, or surgery (including dental work). Women with vWD can have prolonged heavy menstrual bleeding, they may also have an increased risk of excessive blood loss during pregnancy and childbirth. The severity and frequency of the bleeding episodes in vWD can vary greatly among affected individuals, even within the same family. The bleeding phenotype correlates to some degree with the subtype of VWD, with those with the severest form (Type 3) having the most bleeding. Treatment varies based on the diagnosis. In Types 1 and 2 vWD treatment is usually 'on-demand' (after bleeding occurs) with some patients receiving prophylaxis if they have significant frequent bleeding. On demand treatment may be with oral, intra-nasal or subcutaneous treatments or with intravenous infusions of clotting factor concentrates containing FVIII/vWF. This is the method of treatment for all bleeding and prophylaxis in Type 3 vWD, where for some patients, treatment may be given at home. The lack of routine prophylaxis in Type 1 and 2 vWD means that most patients are reliant on hospital delivered care, which may involve frequent clinic appointments, causing prolonged bleeding due to a lack of timely administration of treatment. This can result in concurrent illnesses such as iron deficiency anaemia, which further impacts on the quality of life of affected individuals and their families. There remains a need for a comprehensive understanding of the experience of people with vWD across the whole spectrum of subtypes in order to identify: - The nature and range of symptoms that people experience and how these vary with the different disease subtypes - The variability in pathways through which patients progress to access appropriate care - The impact of living with vWD on the individual's quality of life. ;

Related Conditions & MeSH terms

• Von Willebrand Diseases

• NCT number: NCT06064643
• Study type: Observational
• Source: Haemnet
• Contact: Simon Fletcher, MA
• Phone: 07891038065
• Email: simon@haemnet.com
• Status: Recruiting
• Start date: December 8, 2023
• Completion date: December 31, 2024